Dupilumab_Metastatic NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

Dupilumab

three q3w cycles

DRUG

PD-1/PD-L1 blockade

SOC immunotherapy with PD-1/PD-L1 blockade

DRUG

Anakinra

100 mg daily injection for Three q3w cycles

Trial Locations (2)

10003

RECRUITING

Tisch Cancer Institute, Mount Sinai Hospital, New York

10011

WITHDRAWN

The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York

All Listed Sponsors
lead

Thomas Marron

OTHER